EndoGene.Bio
Paris
About EndoGene.Bio
Endogene.bio was founded to solve the lack of molecular data that keeps endometriosis a clinical black box. By analyzing key cells in menstrual blood, the company delivers tissue-level insights with the convenience of a liquid biopsy. Its platform integrates a proprietary database of single-cell epigenetics, transcriptomics with omics ML advanced algorithms to enable earlier diagnosis, patient stratification, and targeted drug discovery. With proprietary datasets, clinical validation, and pharma interest, endogene.bio is unlocking molecular medicine in a €180B+ women’s health market.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $3.1M
- Funding stage: Seed
- Last round: Pre-Seed (Jun 2023)
- Website: endogene.bio
- Phone: [email protected]
Industries & Categories
Analytics, Biotechnology, Health Care, Health Diagnostics, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/endogene-bio-60591 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.